Permeability Factors in Focal and Segmental Glomerulosclerosis

Advances in Chronic Kidney Disease

Volumn 21, Issue 5, 2014, Pages 417-421

  Reiser, Jochen ^a,b,c   Nast, Cynthia C ^a,b,c   Alachkar, Nada ^a,b,c  

^a RUSH MEDICAL COLLEGE   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Permeability factor; Recurrent focal and segmental glomerulosclerosis; Soluble urokinase receptor; SuPAR

Indexed keywords

ACTIN BINDING PROTEIN; ANGIOTENSIN 1 RECEPTOR; APOLIPOPROTEIN A1; AUTOANTIBODY; CARDIOTROPHIN-LIKE CYTOKINE; CELL ADHESION MOLECULE; CYTOKINE; PHOSPHOPROTEIN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; UROKINASE RECEPTOR; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

CELL MEMBRANE PERMEABILITY; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS; HUMAN; IMMUNOLOGY; METABOLISM; PODOCYTE;

APOLIPOPROTEIN A-I; AUTOANTIBODIES; CELL ADHESION MOLECULES; CELL MEMBRANE PERMEABILITY; CYTOKINES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PODOCYTES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 3; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84906725940     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.05.010     Document Type: Review

References (34)

1. Haas M., Meehan S.M., Karrison T.G., Spargo B.H. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997, 30(5):621-631.
2. Kitiyakara C., Eggers P., Kopp J.B. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004, 44(5):815-825.
3. Reiser J., Pixley F.J., Hug A., et al. Regulation of mouse podocyte process dynamics by protein tyrosine phosphatases rapid communication. Kidney Int 2000, 57(5):2035-2042.
4. Wei C., El Hindi S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17(8):952-960.
5. Savin V.J., Sharma R., Sharma M., et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996, 334(14):878-883.
6. Sharma M., Sharma R., McCarthy E.T., Savin V.J. "The FSGS factor:" enrichment and invivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999, 10(3):552-561.
7. Dall'Amico R., Ghiggeri G., Carraro M., et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 1999, 34(6):1048-1055.
8. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002, 3(12):932-943.
9. Sier C.F., Stephens R., Bizik J., et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998, 58(9):1843-1849.
10. Wei C., Möller C.C., Altintas M.M., et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008, 14(1):55-63.
11. Zhang B., Shi W., Ma J., et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med 2012, 90(12):1407-1420.
12. Wei C., Trachtman H., Li J., et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012, 23(12):2051-2059.
13. Cara-Fuentes G., Wei C., Segarra A., et al. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance. Pediatr Nephrol 2014, 29(8):1363-1371.
14. Sever S., Trachtman H., Wei C., Reiser J. Is there clinical value in measuring suPAR levels in FSGS?. Clin J Am Soc Nephrol 2013, 8(8):1273-1275.
15. Thunø M., Macho B., Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009, 27(3):157-172.
16. Maas R.J.H., Wetzels J.F.M., Deegens J.K.J. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int 2012, 81(10):1043-1044.
17. Bock M.E., Price H.E., Gallon L., Langman C.B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single center report. Clin J Am Soc Nephrol 2013, 8(8):1304-1311.
18. Naesens M., Meijers B., Sprangers B. suPAR and FSGS: the gap between bench and bedside. Transplantation 2013, 96(4):368-369.
19. Sinha A., Bajpai J., Saini S., et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int 2014, 85(3):649-658.
20. Wada T., Nangaku M., Maruyama S., et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int 2014, 85(3):641-648.
21. Meijers B., Maas R.J.H., Sprangers B., et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 2014, 85(3):636.
22. Segarra A., Jatem E., Quiles M.T., et al. Nefrologia 2014, 34(1):46-52. [Article in Spanish].
23. Harris J.J., McCarthy H.J., Ni L., et al. Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. J Pathol 2013, 229(5):660-671.
24. Charba D.S., Wiggins R.C., Goyal M., et al. Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (P(alb)). Am J Physiol Renal Physiol 2009, 297(1):138-144.
25. McCarthy E.T., Sharma M., Savin V.J. Circulating permeability factor in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5(11):2115-2121.
26. Kim E.M., Striegel J., Kim Y., Matas A.J., Najarian J.S., Mauer S.M. Recurrence of steroid-resistant nephrotic syndrome in kidney transplants is associated with increased acute renal failure and acute rejection. Kidney Int 1994, 45(5):1440-1445.
27. Tejani A., Stablein D.H. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992, 2(suppl 12):258-263.
28. Striegel J.E., Sibley R.K., Fryd D.S., Mauer S.M. Recurrence of focal segmental sclerosis in children following renal transplantation. Kidney Int Suppl 1986, 19:44-50.
29. Alachkar N., Wei C., Arend L.J., et al. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy. Transplantation 2013, 96(7):649-656.
30. Lopez-Hellin J., Cantarell C., Jimeno L., et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transplant 2013, 13(2):493-500.
31. Meehan S.M., Pascual M., Williams W.W., et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 1998, 65(9):1192-1197.
32. Shimizu A., Higo S., Fujita E., Mii a, Kaneko T. Focal segmental glomerulosclerosis after renal transplantation. Clin Transplant 2011, 25(suppl 23):6-14.
33. Alachkar N., Gupta G., Montgomery R.A. Angiotensin antibodies andfocal segmental glomerulosclerosis. N Engl J Med 2013, 368(10):971-973.
34. Ponticelli C., Moromi G., Glassock R.J. De novo glomerular diseases after renal transplantation. Clin J Am Soc Nephrol 2014.